934665-46-0

Usage

Uses

Used in Pharmaceutical Research and Development:
1-Azetidinecarboxylic acid, 3-ethylidene-, 1,1-diMethylethyl ester is utilized as a building block in the synthesis of various drug molecules. Its unique structure allows for the creation of novel compounds with potential therapeutic applications.
Used in Materials Science:
In the field of materials science, 1-Azetidinecarboxylic acid, 3-ethylidene-, 1,1-diMethylethyl ester has been studied for its potential applications in the development of polymers and other advanced materials. Its properties may contribute to the creation of innovative materials with specific characteristics.
Used in Organic Chemistry and Chemical Synthesis:
1-Azetidinecarboxylic acid, 3-ethylidene-, 1,1-diMethylethyl ester's unique structure and properties make it a topic of interest in organic chemistry and chemical synthesis. Researchers explore its reactivity and potential use in the formation of new chemical entities, contributing to the advancement of synthetic methodologies and the discovery of new chemical compounds.

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1530-32-1 ethyltriphenylphosphonium bromide 

Downstream Products

• 1373446-59-3 C₁₃H₁₇NO₄ 
• 1373446-69-5 phenylmethyl 3-[(1S)-1-({[(1,1-dimethylethyl)oxy]carbonyl}amino)ethyl]-3-hydroxyazetidine-1-carboxylate 

Relevant academic research and scientific papers

BICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Novel carboxamide-based allosteric MEK inhibitors: Discovery and optimization efforts toward XL518 (GDC-0973)

The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types. Mutations associated with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK. Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer. Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metabolism and safety profile versus PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S) -piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (1). XL518 exhibits robust in vitro and in vivo potency and efficacy in preclinical models with sustained duration of action and is currently in early stage clinical trials.

METHODS OF USING MEK INHIBITORS

The present invention provides methods of treating cancer by administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS

A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a MEK compound of Formula I(M), or a pharmaceutical composition comprising a therapeutically effective amount of a MEK compound of Formula I(M) and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of a JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, wherein the MEK compound of Formula I(M) and JAK-2 compound of Formula I(J) are as defined in the specification.